Changing Treatment Landscape Expands Patient Population
The treatment landscape for conditions requiring anticoagulation, such as atrial fibrillation (AF), venous thromboembolism (VTE), and stroke prevention, has evolved dramatically in recent years. Once limited largely to warfarin, an anticoagulant drug first approved in the 1950s, clinicians now have several newer drug classes to choose from that do not require routine monitoring of international normalized ratios (INRs). ... Read more
